- \n
- Research reinforces the significance of genomic and epigenomic profiling approaches to characterize tumor types, identify biomarkers, and support risk stratification<\/i><\/li>\n
- Presentations reflect Guardant\u2019s strong biopharma and academic collaborations, along with public-private partnerships in Europe<\/i><\/li>\n<\/ul>\n
PALO ALTO, Calif.–(BUSINESS WIRE<\/a>)–
\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts\u2014<\/b>including five rapid oral presentations\u2014demonstrating advances in methylation-based circulating tumor DNA (ctDNA) monitoring and liquid biopsy technology across lung, colorectal, and gastric cancers at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain.<\/p>\n\nThe studies span Guardant’s cancer portfolio, including tissue-free minimal residual disease (MRD) surveillance, treatment response, and resistance research. Significant studies were conducted independently by industry collaborators, academic institutions, and Guardant\u2019s public-private partners using the company\u2019s technologies and\/or real-world data, underscoring the wide adoption of its platform across the research community.<\/p>\n
\n\u201cAt ESMO, we will showcase how InfinityAI is advancing our portfolio, strengthening the clinical relevance of our data, and delivering value to patients, healthcare professionals, and biopharma partners,\u201d said Helmy Eltoukhy, Guardant Health chairman and co-CEO. \u201cWe look forward to presenting new findings and connecting with the oncology community to discuss how Guardant\u2019s solutions can advance cancer care globally.\u201d<\/p>\n
\nKey data that will be presented include:<\/p>\n
- \n
- \nRapid Oral 283RO<\/a>: Assessing bemarituzumab in patients with advanced gastric and gastroesophageal junction cancer by fibroblast growth factor receptor 2 (FGFR2) amplification status in the FORTITUDE study, which suggests that FGFR2 amplification may identify a more treatment-sensitive subgroup.
\n
Friday, Oct. 23, 2026, Session: 4:15-5:45 p.m., Presentation: 5:19-5:24 p.m., Location: Almeria Auditorium – Hall 9<\/p>\n<\/li>\n<\/ul>\n- \n
- \nRapid Oral LBA73<\/a>: Evaluating ctDNA-guided treatment intensification in untreated advanced or metastatic EGFR-mutant non-small cell lung cancer (NSCLC) to identify patients who may benefit from intensified first-line therapy in the PACE-LUNG study\u2014a multicenter, Phase II trial of additional chemotherapy for patients with persistent EGFR-mutant ctDNA in plasma at Week 3 after starting first-line osimertinib.
\n
Saturday, October 24, 2026, Session: 8:30-10 a.m., Presentation: 8:30-8:35 a.m., Location: Almeria Auditorium – Hall 9<\/p>\n<\/li>\n<\/ul>\n- \n
- \nRapid Oral 2636RO<\/a>: Characterizing resistance mechanisms and predictors of early progression and long-term response to lorlatinib from the CROWN study. Findings suggest that baseline genomic complexity and on-treatment changes in methylation-based tissue-free assays may help identify patients at risk of early progression.
\n
Saturday, Oct. 24, 2026, Session: 8:30-10 a.m., Presentation: 9:05-9:10 a.m., Location: Almeria Auditorium – Hall 9<\/p>\n<\/li>\n<\/ul>\n- \n
- \nPoster 4403P<\/a>: Using serial Guardant360\u00ae<\/sup> Liquid testing in a Phase 2 study with MD Anderson to examine clonal and subclonal resistance during anti-EGFR rechallenge in metastatic colorectal cancer to distinguish genuine resistance evolution from changes caused by fluctuating ctDNA levels, potentially improving patient selection for anti-EGFR rechallenge.
\n
Friday, October 23, 2026, Session: 3:15-4 p.m.<\/p>\n<\/li>\n<\/ul>\n- \n
- \nPoster 2566P<\/a>: Exploring post-surgical MRD and pathological complete response (pCR) after perioperative nivolumab in resectable Stage III NSCLC. In this exploratory analysis from NADIM II, pCR was associated with MRD negativity and excellent 5-year survival. In non-pCR patients, MRD negativity identified patients with favorable long-term outcomes, whereas detectable MRD defined a high-risk subgroup with early recurrence.
\n
Monday, October 26, 2026, Session: 12-12:45 p.m.<\/p>\n<\/li>\n<\/ul>\nAdditional Guardant Health presentations at ESMO 2026<\/b><\/p>\n
- \nPoster 2566P<\/a>: Exploring post-surgical MRD and pathological complete response (pCR) after perioperative nivolumab in resectable Stage III NSCLC. In this exploratory analysis from NADIM II, pCR was associated with MRD negativity and excellent 5-year survival. In non-pCR patients, MRD negativity identified patients with favorable long-term outcomes, whereas detectable MRD defined a high-risk subgroup with early recurrence.
- \nPoster 4403P<\/a>: Using serial Guardant360\u00ae<\/sup> Liquid testing in a Phase 2 study with MD Anderson to examine clonal and subclonal resistance during anti-EGFR rechallenge in metastatic colorectal cancer to distinguish genuine resistance evolution from changes caused by fluctuating ctDNA levels, potentially improving patient selection for anti-EGFR rechallenge.
- \nRapid Oral 2636RO<\/a>: Characterizing resistance mechanisms and predictors of early progression and long-term response to lorlatinib from the CROWN study. Findings suggest that baseline genomic complexity and on-treatment changes in methylation-based tissue-free assays may help identify patients at risk of early progression.
- \nRapid Oral LBA73<\/a>: Evaluating ctDNA-guided treatment intensification in untreated advanced or metastatic EGFR-mutant non-small cell lung cancer (NSCLC) to identify patients who may benefit from intensified first-line therapy in the PACE-LUNG study\u2014a multicenter, Phase II trial of additional chemotherapy for patients with persistent EGFR-mutant ctDNA in plasma at Week 3 after starting first-line osimertinib.
- Presentations reflect Guardant\u2019s strong biopharma and academic collaborations, along with public-private partnerships in Europe<\/i><\/li>\n<\/ul>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20261019515698\/en\/2768869\/3\/GuardantHealthMasterLogo_ND_RGB_3x.jpg\")
<\/td>\n<\/tr>\n